These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 7196234)
1. Relationship between the pharmacodynamics and pharmacokinetics of two oral sustained-release formulations of isosorbide dinitrate in normal man. Johnson KI; Gladigau V; Schnelle K Arzneimittelforschung; 1981; 31(6):1026-9. PubMed ID: 7196234 [TBL] [Abstract][Full Text] [Related]
2. Finger pulse plethysmographic effects of two oral sustained-release formulations of isosorbide dinitrate in normal man. Schnelle K; Fenzl E; Johnson KI; Gladigau V; Schinz A Arzneimittelforschung; 1981; 31(5):840-3. PubMed ID: 7196747 [TBL] [Abstract][Full Text] [Related]
3. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate]. Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739 [TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetics of 14C-isosorbide dinitrate after administration in various sustained-release formulations]. Chasseaud LF; Taylor T; Major RM; Taylor IW; Luckow V; Darragh A; Lambe RF Arzneimittelforschung; 1983; 33(9):1298-301. PubMed ID: 6685511 [TBL] [Abstract][Full Text] [Related]
5. Plasma levels of isosorbide dinitrate and its main metabolites following oral administration of two sustained release formulations in normal man. Gladigau V; Neurath G; Dünger M; Schnelle K; Johnson KI Arzneimittelforschung; 1981; 31(5):835-40. PubMed ID: 7196746 [TBL] [Abstract][Full Text] [Related]
6. [Pharmacodynamic effects of the sustained-release tablet of isosorbide dinitrate and its bioavailability in conscious dogs (author's transl)]. Kogi K; Chida S; Kimura T; Saito T Nihon Yakurigaku Zasshi; 1980 Mar; 76(2):99-107. PubMed ID: 7399370 [TBL] [Abstract][Full Text] [Related]
7. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations. Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789 [TBL] [Abstract][Full Text] [Related]
8. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations]. Geigenberger A; Degen J; Maier-Lenz H Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839 [TBL] [Abstract][Full Text] [Related]
9. [Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions]. Rietbrock N; Knoll J; Merz PG; Menke G Dtsch Med Wochenschr; 1985 Nov; 110(47):1821-5. PubMed ID: 3905327 [TBL] [Abstract][Full Text] [Related]
10. Plasma isosorbide dinitrate concentrations and effect after chewable and high-dose, sustained-release formulations. Galeazzi RL; Platzer R; Reutemann G Int J Clin Pharmacol Ther Toxicol; 1983 Aug; 21(8):387-93. PubMed ID: 6629543 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration. Abshagen U; Betzien G; Endele R; Kaufmann B; Neugebauer G Eur J Clin Pharmacol; 1985; 27(6):637-44. PubMed ID: 3987768 [TBL] [Abstract][Full Text] [Related]
12. Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man. Laufen H; Aumann M; Leitold M Arzneimittelforschung; 1983; 33(7):980-4. PubMed ID: 6684933 [TBL] [Abstract][Full Text] [Related]
13. [Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration]. Keller-Stanislawski B; Marschner JP; Rietbrock N Arzneimittelforschung; 1992 Jan; 42(1):17-20. PubMed ID: 1586374 [TBL] [Abstract][Full Text] [Related]
14. First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man. Abshagen U; Spörl-Radun S Eur J Clin Pharmacol; 1981; 19(6):423-9. PubMed ID: 7250175 [TBL] [Abstract][Full Text] [Related]
15. [Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations]. Scheidel B; Blume H; Stenzhorn G; Siewert M; Babej-Dölle RM Arzneimittelforschung; 1991 Mar; 41(3):212-8. PubMed ID: 1867657 [TBL] [Abstract][Full Text] [Related]
16. [Hemodynamic effects of a transdermal formulation of isosorbide dinitrate and its pharmacokinetics in conscious dogs]. Kogi K; Tanaka O; Kimura T; Saito T Nihon Yakurigaku Zasshi; 1982 Oct; 80(4):279-88. PubMed ID: 7152395 [TBL] [Abstract][Full Text] [Related]
18. [Assay of plasma isosorbide dinitrate and its metabolites after oral administration of immediate and delayed-action forms]. Audry E; Dallet P; Dubost JP; Langlois MH; Ernouf D; Narcisse G Ann Pharm Fr; 1989; 47(4):235-41. PubMed ID: 2637644 [TBL] [Abstract][Full Text] [Related]
19. Influence of diet on the single-dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate. Sata H; Inoue K; Nii T; Kuroda T Biol Pharm Bull; 1997 Oct; 20(10):1111-5. PubMed ID: 9353575 [TBL] [Abstract][Full Text] [Related]
20. Contribution of isosorbide-5-mononitrate, a major metabolite of isosorbide dinitrate (ISDN), to the hemodynamic effect of ISDN administered orally in conscious dogs. Kogi K; Satoh T Jpn J Pharmacol; 1987 Jul; 44(3):249-57. PubMed ID: 3656782 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]